Drug
Piflufolastat clinical trials
Also written 18F-DCFPyL and PYLARIFY.
Keep track of what changes. Save the piflufolastat studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Brand
Other names
Studies by the year they started
30 studies that test it; most in 2024 (5)
| Year | Studies |
|---|---|
| 2014 | 1 |
| 2015 | 2 |
| 2016 | 3 |
| 2017 | 2 |
| 2018 | 4 |
| 2019 | 3 |
| 2020 | 1 |
| 2021 | 2 |
| 2022 | 2 |
| 2023 | 3 |
| 2024 | 5 |
| 2025 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 5 · Other 25
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (7) · National Cancer Institute (NCI) (5) · Lantheus Medical Imaging (2) · Progenics Pharmaceuticals, Inc. (2) · M.D. Anderson Cancer Center (1) · Columbia University (1) · University of Wisconsin, Madison (1) · Blue Earth Diagnostics (1)
Often tested with
Tested in the same studies.
Sodium fluoride f-18 (2) · Flotufolastat F 18 (1) · Enzalutamide (1) · Abiraterone (1)
Studies
Open first, then newest update. How each study uses piflufolastat is read from its arms, and is right about nine times in ten.
Testing it · 30
- Evaluation of the Change in PSMA Expression in Prostate Cancer in Response to Hormonal TherapyRecruitingPhase 4OHSU Knight Cancer InstituteNCT05919329Written as Piflufolastat
- 18F-DCFPyL Imaging as a Method to Assess Treatment Response to Stereotactic Body Radiation TherapyRecruitingPhase 2National Cancer Institute (NCI)NCT05155046Written as 18F-DCFPyL
- Image-guided Focal Brachytherapy Utilizing Combined 18F-DCFPyl PET/CTRecruitingEarly Phase 1Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsNCT03861676Written as (18F)DCFPyL
- Pilot of 18F-DCFPyL-PSMA PET in mCRPC Patients Receiving 117Lu-Vipivotide TetraxetanRecruitingPhase 4Brigham and Women's HospitalNCT06099093Written as 18F-DCFPyl
- Ultralow Dose PET Imaging for PSMA ExpressionRecruitingPhase 2Akiva MintzNCT06904313Written as Piflufolastat F18
- 18F-DCFPyL PET/CT in High Risk and Recurrent Prostate CancerActive, not recruitingPhase 2National Cancer Institute (NCI)NCT03181867Written as 18F-DCFPyL
- 18F-DCFPyL PSMA- Versus 18F-NaF-PET Imaging for Detection of Metastatic Prostate CancerActive, not recruitingPhase 2National Cancer Institute (NCI)NCT03173924Written as 18F-DCFPyL
- Evaluation of PSMA in HER2- AR+ Metastatic Breast CancerCompletedPhase 2University of Wisconsin, MadisonNCT04573231Written as 18F-DCFPyL
- A Pilot Study to Assess the Clinical Utility of PYLARIFY PET-CT for Detecting Metastasis in Pancreatic Cancer, Hepatocellular Carcinoma and Breast CancerActive, not recruitingPhase 1M.D. Anderson Cancer CenterNCT05394259Written as Piflufolastat F18
- Intrapatient Comparison of Urinary Radioactivity Following Piflufolastat (18F) and Flotufolastat (18F) PET in Men With Low PSA Biochemical Recurrence of Prostate Cancer Following Radical ProstatectomyCompletedPhase 4Blue Earth DiagnosticsNCT06604442Written as piflufolastat (18F)
- Neoadjuvant Androgen Deprivation Therapy Combined With Enzalutamide and Abiraterone Using Multiparametric MRI and 18FDCFPyL PET/CT in Newly Diagnosed Prostate CancerCompletedPhase 2National Cancer Institute (NCI)NCT03860987Written as 18F-DCFPyL
- Study of PSMA-targeted 18F-DCFPyL PET/CT for the Detection of Clinically Significant Prostate CancerActive, not recruitingPhase 2Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsNCT03471650Written as 18F-DCFPyL Injection
- Piflufolastat F 18 PET/CT in Patients With Suspected, or at High Risk for Metastatic ccRCCWithdrawnPhase 2/3Lantheus Medical ImagingNCT07084909Written as piflufolastat F 18
- PSMA-Targeted 18F-DCFPyL PET/MRI for the Detection of Prostate CancerWithdrawnPhase 2Northwestern UniversityNCT04910425Written as Fluorine F 18 DCFPyL
- PYLARIFY® PET/CT or PET/MRI in Men With Favorable Intermediate Risk (FIR) Prostate CancerActive, not recruitingPhase 4Lantheus Medical ImagingNCT06074510Written as Piflufolastat F 18 Intravenous Solution [PYLARIFY]
- 18F-DCFPyL PET/CT in Hepatocellular CarcinomaTerminatedPhase 2National Cancer Institute (NCI)NCT05009979Written as F18-DCFPyL
- 18F-DCFPyL PET/CT Impact on Treatment Strategies for Patients With Prostate CancerCompletedPhase 2VA Greater Los Angeles Healthcare SystemNCT04390880Written as 18F-DCFPyL
- Prostate MRI and Pylarify PSMA PET/CTWithdrawnPhase 4William Beaumont HospitalsNCT05568537Written as Pylarify Piflufolastat Flourine-18 (18F-DCFPyL)
- 18F-DCFPyL Positron Emission Tomography (PET) in Intermediate or High Risk Prostate CancerTerminatedPhase 2Ashok MuthukrishnanNCT04727736Written as 18F-DCFPyL
- Prostate Cancer Monitoring Using [18F]DCFPyL and Blood Based BiomarkersActive, not recruitingPhase 2Columbia UniversityNCT03585114Written as [F-18] DCFPyL
See all 30 studies that test piflufolastat →
Given in every arm · 3 — piflufolastat is usual care beside what is tested
- A Pilot Presurgical Trial of REGN5678 (Anti-PSMA x CD28) in Patients With High-risk, Localized Prostate Cancer Followed by Radical ProstatectomyRecruitingPhase 1/2M.D. Anderson Cancer CenterNCT06085664Written as Piflufolastat F18
- A Phase II Study of AAA617 Alone and AAA617 in Combination With ARPI in Patients With PSMA PET Scan Positive CRPCActive, not recruitingPhase 2Novartis PharmaceuticalsNCT05849298Written as Piflufolastat F 18
- PSMA Therapy and Immunotherapy in Kidney CancerWithdrawnPhase 1/2Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsNCT06361810Written as (F-18)-DCFPyL
Codes
What other systems call piflufolastat · ClinicalTrials.gg INT006070
- MeSH (NLM) C572626piflufolastatConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 82VH67YON8PIFLUFOLASTATConfirmed NLM, Wikidata
- RxNorm 2556617One source FDA
- Wikidata Q27269357piflufolastatConfirmed NLM, Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C572626 | piflufolastat | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 82VH67YON8 | PIFLUFOLASTAT | Confirmed NLM, Wikidata |
| RxNorm | 2556617 | — | One source FDA |
| Wikidata | Q27269357 | piflufolastat | Confirmed NLM, Wikidata |
Also registered as piflufolastat f-18 (UNII 3934EF02T7 · RxNorm 2556616).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.